Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST₁-SST₅; nomenclature as agreed by the NC-IUPHAR Subcommittee on Somatostatin Receptors [9]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14 (SST, P61278)) and somatostatin-28 (SRIF-28 (SST, P61278)). Cortistatin-14 has also been suggested to be an endogenous ligand for somatostatin receptors [5].

[¹²⁵I]Tyr¹¹-SRIF-14, [¹²⁵I]LTT-SRIF-28, [¹²⁵I]CGP 23996 and [¹²⁵I]Tyr¹⁰-CST14 may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype-selective agonists have been synthesised [17]. Octreotide and lanreotide are being used in the treatment of SST₂-expressing neuroendocrine tumors and pasireotide for SST₅-expressing neuroendocrine tumors. A novel peptide somatostatin analogue, veldoreotide (COR-005), has affinity for SST₂, SST₄ and SST₅ receptors and is a potent inhibitor of GH secretion [16,19].

* Key recommended reading is highlighted with an asterisk

* Colao A, Auriemma RS, Lombardi G, Pivonello R. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev., 32 (2): 247-71. [PMID:21123741]

Durán-Prado M, Malagón MM, Gracia-Navarro F, Castaño JP. (2008) Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol. Cell. Endocrinol., 286 (1-2): 63-8. [PMID:18242821]

* Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ et al.. (2018) International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol. Rev., 70 (4): 763-835. [PMID:30232095]

* Hoyer D, Epelbaum J, Feniuk W, Humphrey PPA, Meyerhof W, O'Carroll AM et al.. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edn. Edited by Watson SP, Girdlestone D (IUPHAR Media) 354-364.

* Schulz S, Lehmann A, Kliewer A, Nagel F. (2014) Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol., 171 (7): 1591-9. [PMID:24328848]

* Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov, 2 (12): 999-1017. [PMID:14654798]

1. Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G et al.. (2001) Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology, 142 (1): 477-86. [PMID:11145612]

2. Bruns C, Raulf F, Hoyer D, Schloos J, Lübbert H, Weckbecker G. (1996) Binding properties of somatostatin receptor subtypes. Metab. Clin. Exp., 45 (8 Suppl 1): 17-20. [PMID:8769372]

3. Castro SW, Buell G, Feniuk W, Humphrey PP. (1996) Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells. Br. J. Pharmacol., 117 (4): 639-46. [PMID:8646408]

4. Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, Reubi JC. (2008) Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J. Med. Chem., 51 (13): 4030-7. [PMID:18543899]

5. de Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, Dunlop CL, Siggins GR, Henriksen SJ, Sutcliffe JG. (1996) A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature, 381 (6579): 242-5. [PMID:8622767]

6. Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM, Wurster S. (2005) Superagonism at the human somatostatin receptor subtype 4. J. Pharmacol. Exp. Ther., 312 (1): 332-8. [PMID:15333679]

7. Erchegyi J, Hoeger CA, Low W, Hoyer D, Waser B, Eltschinger V, Schaer JC, Cescato R, Reubi JC, Rivier JE. (2005) Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem, 48: 507-514. [PMID:15658864]

8. Farb TB, Adeva M, Beauchamp TJ, Cabrera O, Coates DA, Meredith TD, Droz BA, Efanov A, Ficorilli JV, Gackenheimer SL et al.. (2017) Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5. Endocrinology, 158 (11): 3859-3873. [PMID:28938487]

9. Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ et al.. (2018) International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol. Rev., 70 (4): 763-835. [PMID:30232095]

10. He S, Ye Z, Truong Q, Shah S, Du W, Guo L, Dobbelaar PH, Lai Z, Liu J, Jian T et al.. (2012) The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes. ACS Med Chem Lett, 3 (6): 484-9. [PMID:24900499]

11. Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K, Neumann P et al.. (2004) SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci. Lett., 361 (1-3): 132-5. [PMID:15135911]

12. Hoyer D, Vassout A, Gentsch C, Enz A, Vigouret JM, Jaton A, Schoeffter P, Kelly P, Wrynn A, Hurth K, Troxler T. (2004) Functional characterization of NVP ACQ090, a somatostatin sst₃ receptor antagonist. Soc Neuroscience Abs,: -.

13. Liu S, Tang C, Ho B, Ankersen M, Stidsen CE, Crider AM. (1998) Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J. Med. Chem., 41 (24): 4693-705. [PMID:9822540]

14. Meyerhof W. (1998) The elucidation of somatostatin receptor functions: a current view. Rev. Physiol. Biochem. Pharmacol., 133: 55-108. [PMID:9600011]

15. Patel YC, Srikant CB. (1994) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology, 135 (6): 2814-7. [PMID:7988476]

16. Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, Jakob W, Saeger W, Schulz S et al.. (2012) DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur. J. Endocrinol., 166 (2): 223-34. [PMID:22065857]

17. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F et al.. (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science, 282 (5389): 737-40. [PMID:9784130]

18. Schmid HA, Schoeffter P. (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology, 80 Suppl 1: 47-50. [PMID:15477717]

19. Shimon I, Rubinek T, Hadani M, Alhadef N. (2004) PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J. Endocrinol. Invest., 27 (8): 721-7. [PMID:15636423]

20. Siehler S, Seuwen K, Hoyer D. (1998) [125I]Tyr10-cortistatin14 labels all five somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol., 357 (5): 483-9. [PMID:9650799]

21. Siehler S, Seuwen K, Hoyer D. (1998) [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur. J. Pharmacol., 348 (2-3): 311-20. [PMID:9652348]

22. Siehler S, Seuwen K, Hoyer D. (1999) Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch. Pharmacol., 360 (5): 488-99. [PMID:10598788]

23. Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW et al.. (1998) Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. U.S.A., 95 (18): 10836-41. [PMID:9724791]

Subcommittee members: Stefan Schulz (Chairperson) Institute of Pharmacology and Toxicology Jena University Hospital Friedrich-Schiller-University Jena, Germany Corinne Bosquet Cancer Research Center of Toulouse (CRCT) INSERM UMR 1037-University Toulouse III Paul Sabatier Toulouse, France Justo P. Castaño Maimonides Institute for Biomedical Research of Cordoba (IMIBIC) Department of Cell Biology, Physiology, and Immunology University of Córdoba Reina Sofia University Hospital CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn) Córdoba, Spain Zsolt Csaba PROTECT INSERM Université Paris Diderot Sorbonne Paris Cité Paris, France Pascal Dournaud PROTECT INSERM Université Paris Diderot Sorbonne Paris Cité Paris, France Hans-Jürgen Kreienkamp Institute of Human Genetics University Medical Center Hamburg-Eppendorf Hamburg, Germany Amelie Lupp Institute of Pharmacology and Toxicology Jena University Hospital Friedrich-Schiller-University Jena, Germany Shlomo Melmed Pituitary Center Department of Medicine Cedars-Sinai Medical Center Los Angeles, California, USA Giovanni Tulipano Unit of Pharmacology Department of Molecular and Translational Medicine University of Brescia Italy Hans-Jürgen Wester Pharmaceutical Radiochemistry Technische Universität München Munich, Germany

Other contributors: Micheal Culler IPSEN 27 Maple Street Milford 01757 MA USA Jacques Epelbaum Institut National de la Sante de la Recherche Medicale INSERM- UNIVERSITE PARIS DESCARTES UMR. 549 2 ter rue d'Alesia Paris F-75014 France Wasyl Feniuk Glaxo Institute of Applied Pharmacology University of Cambridge Department of Pharmacology Tennis Court Road Cambridge CB2 1QJ UK Anthony Harmar (1951-2014) formerly of the University of Edinburgh, Edinburgh, Scotland Rebecca Hills (Past curator) Leo Hofland Division of Endocrinology Department of Internal Medicine Erasmus Medical Center Molewaterplein 50 3015 GE Rotterdam The Netherlands Daniel Hoyer (Past chairperson) Chair and Head Department of Pharmacology and Therapeutics School of Medicine Faculty of Medicine, Dentistry and Health Sciences The University of Melbourne Parkville Victoria 3010 Australia Patrick P. A. Humphrey Glaxo Institute of Applied Pharmacology Department of Pharmacology University of Cambridge Tennis Court Road Cambridge CB2 1QJ UK Wolfgang Meyerhof Department of Molecular Genetics German Institute of Human Nutrition Arthur-Scheunert-Allee 114-116 Potsdam-Rehbruecke D-14558 Germany Anne-Marie O'Carroll Bristol Royal Infirmary University of Bristol Malborough Street Bristol BS2 8HW UK Yogesh C. Patel Department of Medicine McGill University Royal Victoria Hospital Room M3.15 687 Pine Avenue West Montréal Québec H3A 1A1 Canada Terry Reisine ActiveSite Biotech La Jolla CA USA Jean-Claude Reubi Institute of Pathology University of Berne Murtenstrasse 31 Berne CH-3010 Switzerland Marcus Schindler Boehringer Ingelheim Pharma Department of Cardiovascular and MetabolicResearch Biberach D-88397 Germany Herbert Schmid Novartis Pharma AG Novartis Institutes for Biomedical Research Oncology CH-4057 Basel Switzerland Agnes Schonbrunn Department of Pharmacology The University of Texas Medical School PO Box 20708 6431 Fannin Houston TX 77225 USA John E. Taylor Biomeasure 27 Maple Street Milford MA 01757-3650 USA Annamaria Vezzani Department of Neuroscience Istituto di Ricerche Farmacologiche 'Mario Negri' Via Eritrea 62 Milan 20157 Italy